Influence of chronic administration of S 16924 upon its ability to inhibit the locomotion provoked by phencyclidine (PCP)
| Chronic (Dose) | Vehicle | S 16924 (0.16) | S 16924 (2.5) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Acute (dose) | Vehicle | Vehicle | S 16924 (0.16) | S 16924 (2.5) | Vehicle | Vehicle | S 16924 (0.16) | Vehicle | Vehicle | S 16924 (2.5) |
| Acute (dose) | Vehicle | PCP (20.0) | PCP (20.0) | PCP (20.0) | Vehicle | PCP (20.0) | PCP (20.0) | Vehicle | PCP (20.0) | PCP (20.0) |
| Locomotion | 66.5 ± 10.0 | 202.5 ± 46.33-a | 132.7 ± 31.3b | 13.7 ± 6.0b | 75.5 ± 12.4 | 215.3 ± 51.53-a | 58.2 ± 15.3b | 60.5 ± 10.4 | 249.8 ± 67.83-a | 16.5 ± 4.2b |
Doses are in mg/kg, s.c. Data are means ± S.E.M. of locomotor counts. ANOVA as follows: chronic vehicle, F (3,22) = 8.6, P < .001; chronic S 16924 (0.16), F (2,15) = 7.3, < .01 and chronic S 16924 (2.5), F (2,15) = 9.8, P < .001.
↵3-a Significance of differences of vehicle/PCP to respective vehicle/vehicle values and footnote b denotes significance of S 16924/PCP to respective vehicle/PCP values in Newman-Keuls test after ANOVA.
P < .05.